Hospital Frydek-Mistek
Frýdek-Místek, Czechia
NCT Number: NCT03723720
The aim of our study is to compare MAP (mean adenoma per colonoscopy) with ADR (adenoma detection rate) and PDR (polyp detection rate) of all colonoscopists in our department
Looking for future studies?
Notify Me50 year and older
All sexes
Observational
Frýdek-Místek, Czechia
ADR (adenoma detection rate) is generally accepted quality indicator. For possible gaming with ADR other indicators are needed. MAP (mean adenoma per colonoscopy) reflects the quality of examination of entire colon and is considered to be the most objective quality indicator. The aim of our study is to compare MAP with ADR and PDR (polyp detection rate) of all colonoscopists in our department.
We want to retrospectively assess the quality indicators of all colonoscopies from January 2013 to December 2017. We want to calculate ADR, PDR and MAP of all our endoscopists for all colonoscopies in patients over 50 years of age excluding therapeutic, IBD, management of complications and sigmoidoscopies (screening, surveillance, diagnostic) and separately only for screening colonoscopies. Correlations between MAP/ADR and MAP/PDR will be performed using Pearson´s correlation coefficient.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Endoscopic examination of large bowel
Time frame: january 2013 - december 2017
Pearson´s correlation coefficient
Time frame: january 2013 - december 2017
Pearson´s correlation coefficient
Time frame: january 2013 - december 2017
Pearson´s correlation coefficient
Hospital Frydek-Mistek
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04369053
Adenoma, Colon Cancer
Birmingham, Alabama, United States
View Trial DetailsNCT04799080
Breast Cancer, Breast Diseases
Izmir, Çiğli, Turkey (Türkiye)
View Trial DetailsNCT05497726
Colon Neoplasm, Colonic Diseases
Amersfoort, Utrecht, Netherlands
View Trial DetailsNCT03871790
Colo-rectal Cancer, Colon Adenocarcinoma
Lahore, Pakistan
View Trial Details